These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 38341085)
1. Altered States and Social Bonds: Effects of MDMA and Serotonergic Psychedelics on Social Behavior as a Mechanism Underlying Substance-Assisted Therapy. Schmid Y; Bershad AK Biol Psychiatry Cogn Neurosci Neuroimaging; 2024 May; 9(5):490-499. PubMed ID: 38341085 [TBL] [Abstract][Full Text] [Related]
2. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner. Lyvers M; Meester M J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892 [TBL] [Abstract][Full Text] [Related]
4. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. Breeksema JJ; Kuin BW; Kamphuis J; van den Brink W; Vermetten E; Schoevers RA J Psychopharmacol; 2022 Oct; 36(10):1100-1117. PubMed ID: 36017784 [TBL] [Abstract][Full Text] [Related]
5. MDMA Increases Cooperation and Recruitment of Social Brain Areas When Playing Trustworthy Players in an Iterated Prisoner's Dilemma. Gabay AS; Kempton MJ; Gilleen J; Mehta MA J Neurosci; 2019 Jan; 39(2):307-320. PubMed ID: 30455187 [TBL] [Abstract][Full Text] [Related]
7. MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults. Jones GM; Nock MK J Psychopharmacol; 2022 Jan; 36(1):46-56. PubMed ID: 34983249 [TBL] [Abstract][Full Text] [Related]
8. Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine. De Gregorio D; Aguilar-Valles A; Preller KH; Heifets BD; Hibicke M; Mitchell J; Gobbi G J Neurosci; 2021 Feb; 41(5):891-900. PubMed ID: 33257322 [TBL] [Abstract][Full Text] [Related]
9. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders. Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717 [TBL] [Abstract][Full Text] [Related]
10. [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges]. Majić T; Jungaberle H; Schmidt TT; Zeuch A; Hermle L; Gallinat J Fortschr Neurol Psychiatr; 2017 Jul; 85(7):383-392. PubMed ID: 28768346 [No Abstract] [Full Text] [Related]
11. Characterizing Thalamocortical (Dys)connectivity Following D-Amphetamine, LSD, and MDMA Administration. Avram M; Müller F; Rogg H; Korda A; Andreou C; Holze F; Vizeli P; Ley L; Liechti ME; Borgwardt S Biol Psychiatry Cogn Neurosci Neuroimaging; 2022 Sep; 7(9):885-894. PubMed ID: 35500840 [TBL] [Abstract][Full Text] [Related]
12. Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes. Jones GM; Nock MK J Psychopharmacol; 2022 Jan; 36(1):57-65. PubMed ID: 34983261 [TBL] [Abstract][Full Text] [Related]
13. Acute subjective effects in LSD- and MDMA-assisted psychotherapy. Schmid Y; Gasser P; Oehen P; Liechti ME J Psychopharmacol; 2021 Apr; 35(4):362-374. PubMed ID: 33853422 [TBL] [Abstract][Full Text] [Related]
14. MDMA enhances emotional empathy and prosocial behavior. Hysek CM; Schmid Y; Simmler LD; Domes G; Heinrichs M; Eisenegger C; Preller KH; Quednow BB; Liechti ME Soc Cogn Affect Neurosci; 2014 Nov; 9(11):1645-52. PubMed ID: 24097374 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis. Yao Y; Guo D; Lu TS; Liu FL; Huang SH; Diao MQ; Li SX; Zhang XJ; Kosten TR; Shi J; Bao YP; Lu L; Han Y Psychiatry Res; 2024 May; 335():115886. PubMed ID: 38574699 [TBL] [Abstract][Full Text] [Related]
17. Validation of the Swiss Psychedelic Side Effects Inventory: Standardized assessment of adverse effects in studies of psychedelics and MDMA. Calder AE; Hasler G J Affect Disord; 2024 Nov; 365():258-264. PubMed ID: 39168165 [TBL] [Abstract][Full Text] [Related]
18. Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms. Inserra A; De Gregorio D; Gobbi G Pharmacol Rev; 2021 Jan; 73(1):202-277. PubMed ID: 33328244 [TBL] [Abstract][Full Text] [Related]
19. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020. Barnett BS; Parker SE; Weleff J Int J Drug Policy; 2022 Jan; 99():103473. PubMed ID: 34624734 [TBL] [Abstract][Full Text] [Related]
20. A Brief Historical Overview of Psychedelic Research. Geyer MA Biol Psychiatry Cogn Neurosci Neuroimaging; 2024 May; 9(5):464-471. PubMed ID: 38000715 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]